March 16th 2024
A phase 2 trial showed favorable antitumor activity when tislelizumab plus chemotherapy was used for patients with locally advaned cervical cancer.
Equalizing Inequities™ in Multiple Myeloma Care: Shining a Light on Current Barriers and Opportunities for Improved Outcomes
View More
Community Practice Connections™: 14th Annual International Symposium on Ovarian Cancer and Other Gynecologic Malignancies
View More
Medical Crossfire®: How Do Clinicians Integrate the Latest Evidence in Treating Ovarian Cancer to Personalize Care?
View More
Medical Crossfire®: Where Are We in the World of ADCs? From HER2 to CEACAM5, TROP2, HER3, CDH6, B7H3, c-MET and Beyond!
View More
Community Oncology Connections™: Overcoming Barriers to Testing, Trial Access, and Equitable Care in Cancer
View More
Community Practice Connections™: 5th Annual Precision Medicine Symposium – An Illustrated Tumor Board
View More
Breast and Cervical Cancer Early Detection Program to Expand
December 1st 1996WASHINGTON--For the first time since its inception in 1991, funds from the Breast and Cervical Cancer Early Detection Program will flow to all 50 states in fiscal 1997, the Department of Health and Human Services announced.
Folate: Effects on Carcinogenesis and the Potential For Cancer Chemoprevention
November 1st 1996Drs. Mason and Levesque thoroughly review data from intervention trials and epidemiologic studies that suggest a role for folate in preventing cancer of the colorectum and, to a lesser degree, cancers of the uterine cervix, lung, esophagus, and stomach. The authors also provide a comprehensive discussion of the possible mechanisms by which folate may prevent cancer, in particular, the relationship between folate status and DNA methylation.
ThinPrep Pap Test Offers Improved Slide Preparation
July 1st 1996MARLBOROUGH, Mass--Cytyc Corporation's ThinPrep 2000 System for cervical cancer screening has received FDA approval and is now available. The system offers an improved method of preparing Pap smears over the conventional method, leading to fewer retests due to compromised smears and potentially fewer missed abnormalities.
DFMO Shows Potential in the Prevention of Cervical Cancer
June 1st 1996NEW ORLEANS--In a phase I trial from M.D. Anderson Cancer Center, the chemopreventive agent difluorometh-ylornithine (DFMO) produced significant regression of cervical intraepithelial neoplasia (CIN) grade 3, Michele Follen Mitchell, MD, reported at the Society of Gynecologic Oncologists meeting.
Cervical Cancer: Behavioral Changes Could Save Most Women
June 1st 1996Cervical cancer's slow, noticeable growth makes it "an ideal disease" for screening, but poor choices--like not getting a Pap smear or having unprotected sex as young adults--give the disease a disastrous head start, a University of Wisconsin Medical
HPV Is the Culprit in Virtually All Cervical Cancers--NIH Panel
May 1st 1996BETHESDA, Md--Of the 4,900 US deaths each year from cervical cancer, virtually all could have been prevented by routine Pap smears, and nearly all cases could be prevented by practicing safe sex to avoid infection with the human papillomavirus (HPV), a panel of independent experts appointed by the NIH said in a consensus statement.
Women Smokers Have High Nicotine Concentrations in Their Cervical Mucus
May 1st 1995SAN FRANCISCO--For 15 years, there has been a clear, epidemiologic link between cigarette smoking and an increased risk of cervical cancer, Steven Waggoner, MD, said at a poster presentation at the Society of Gynecologic Oncol-ogists meeting.
Human Papillomaviruses: Their Clinical Significance in the Management of Cervical Carcinoma
April 1st 1995Studies have shown a strong association between certain human papillomaviruses and the development of cervical carcinoma and its precursor lesions. The oncogenic potential of papillomaviruses has been clearly